商业媒体私人有限

2023年8月4日

影像学分:财富印度healthtech独角兽已经留出INR 100 Cr构建五个病人护理中心在达卡和Chattogram未来两年Pristyn保健还计划招聘200名员工在各部门在孟加拉国作为计划的一部分,成立于2018年,Pristyn关心最近的头条之后解雇员工裁员和暂停Lybrate的创始人healthtech独角兽Pristyn保健开始业务在孟加拉国,留出INR 100 Cr在未来两年的扩张在邻国。创业公司,专门从事外科治疗计划有五个病人护理中心在达卡和Chattogram吉大港FY24年底。Pristyn保健还计划招聘200名员工在各部门在孟加拉国的计划。“与该国(孟加拉国)医疗市场将达到140亿美元,到2023年底,我们致力于医疗保健在孟加拉国的增长。未来两年,我们将投资印度卢比100 Cr建立健壮的医疗基础设施,“Pristyn护理创始人Harsimarbir辛格说。启动还告诉Inc42它已经运行一个飞行员在达卡在过去的三个月,在孟加拉首都与五医院合作。启动一组35护理协调员已经在达卡,协调手术和初级护理。由辛格,Vaibhav Kapoor博士和博士Garima Sawhney 2018年,Pristyn保健提供了先进的二级护理手术通过其网络超过800家医院,诊所,超过200和400 +内部super-speciality外科医生。启动声称,它提供了治疗50多个疾病42个城市,拥有150 k +病人治疗。推荐给你:1月6日,2023年Pristyn护理后进入独角兽俱乐部在2021年底筹集96美元Mn在其系列E轮从高峰十五合作伙伴(然后红杉资本印度),老虎全球,冬天首都Eriq资本和蜂鸟公司估值为14亿美元。 The Gurugram-based startup has raised a total funding of over $177 Mn to date. Last year, Pristyn Care acquired New Delhi-based healthcare startup Lybrate for an undisclosed amount. The healthtech unicorn competes against the likes of MediBuddy, Practo and PharmEasy. Trouble Simmering Underneath The startup was shrouded in controversy in March this year as it fired 300-350 employees across departments , Inc42 had exclusively reported at the time. The layoffs impacted sales, tech and product teams, according to Inc42 sources. Inc42 further learnt that GST officials visited Pristyn Care’s office a few months ago seeking clarifications about the startup’s operations. The healthtech startup said the department had some simple questions about its business model. While the startup has not filed its financial statement for financial year 2021-22 (FY22) with the Ministry of Corporate Affairs (MCA), it reported a loss of INR 63.5 Cr in FY21 on operating revenue of INR 96 Cr. The healthtech unicorn was also shaken last month as it reportedly suspended the founders of Lybrate for filing a default notice against the startup. The cofounders – Rahul Narang and Saurabh Arora – were shown the door for filing a default notice against Pristyn Care for outstanding payments emanating out of the acquisition deal.